- Home
- DOCS vs BMRN Comparison
DOCS vs BMRN Comparison
Compare DOCS & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOCS
- BMRN
- Stock Information
- Founded
- DOCS 2010
- BMRN 1996
- Country
- DOCS United States
- BMRN United States
- Employees
- DOCS N/A
- BMRN N/A
- Industry
- DOCS Retail: Computer Software & Peripheral Equipment
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- DOCS Technology
- BMRN Health Care
- Exchange
- DOCS Nasdaq
- BMRN Nasdaq
- Market Cap
- DOCS 12.3B
- BMRN 9.9B
- IPO Year
- DOCS 2021
- BMRN 1999
- Fundamental
- Price
- DOCS $50.26
- BMRN $55.20
- Analyst Decision
- DOCS Buy
- BMRN Buy
- Analyst Count
- DOCS 20
- BMRN 19
- Target Price
- DOCS $68.55
- BMRN $90.26
- AVG Volume (30 Days)
- DOCS 1.7M
- BMRN 2.8M
- Earning Date
- DOCS 11-06-2025
- BMRN 10-27-2025
- Dividend Yield
- DOCS N/A
- BMRN N/A
- EPS Growth
- DOCS 42.88
- BMRN 59.53
- EPS
- DOCS 1.25
- BMRN 2.68
- Revenue
- DOCS $621,329,000.00
- BMRN $3,094,001,000.00
- Revenue This Year
- DOCS $13.54
- BMRN $13.32
- Revenue Next Year
- DOCS $11.26
- BMRN $7.51
- P/E Ratio
- DOCS $39.96
- BMRN $20.23
- Revenue Growth
- DOCS 20.21
- BMRN 12.39
- 52 Week Low
- DOCS $47.66
- BMRN $50.76
- 52 Week High
- DOCS $85.21
- BMRN $73.51
- Technical
- Relative Strength Index (RSI)
- DOCS 20.87
- BMRN 56.52
- Support Level
- DOCS $65.22
- BMRN $50.76
- Resistance Level
- DOCS $67.10
- BMRN $55.34
- Average True Range (ATR)
- DOCS 2.19
- BMRN 1.75
- MACD
- DOCS -1.55
- BMRN 0.35
- Stochastic Oscillator
- DOCS 6.95
- BMRN 71.44
About DOCS Doximity Inc.
Doximity Inc is a digital platform for U.S. medical professionals. The cloud-based platform provides members with tools specifically built for medical professionals, enabling them to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers and on-call schedules.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.